Overexpression of AXL, or its ligand GAS6, is frequently associated with the mesenchymal subtype and poor prognosis in GBM, and both AXL and GAS6 are listed as cancer driver genes in a recent Pan-Cancer CPTAC study (31–34). Here, GAS6 is linked to cancer.